The Chen-Huang Center for EGFR Mutant Lung Cancers aims to advance care and research of EGFR-mutant lung cancer with clinical trials of new and novel therapies supported by lab research and studies of cancer genetics.
Our trials include studies for patients with newly diagnosed EGFR-mutant lung cancer and patients whose cancer has advanced on current therapy, in addition to studies of cancer genetics. The trials listed here are updated regularly, so check back often.
A patient must meet certain requirements to participate in a clinical trial. Your doctor or another member of your health care team is the best resource for knowing your treatment options and eligibility.
Trials for Patients With Newly Diagnosed EGFR-Mutant Cancers
- Trial 22-698: An Open-Label, Phase 1/1b Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Principal investigator: Julia Rotow, MD - Trial 25-035: A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Principal investigator: Narjust Florez, MD
Trials for Patients With Previously Treated EGFR-Mutant Cancers
- Trial 23-568: A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Principal investigator: Pasi A. Jänne, MD, PhD - Trial 23-382: A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-Cancer Agents in Patients with Advanced Solid Tumors | Dana-Farber Cancer Institute
Principal investigator: Pasi A. Jänne, MD, PhD - Trial 23-327: A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects with Advanced/Metastatic Solid Tumors
Principal investigator: Julia Rotow, MD - Trial 25-004: Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Principal investigator: Pasi A. Jänne, MD, PhD - Trial 25-284: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
Principal investigator: Julia Rotow, MD
Other Clinical Trials Accepting Patients With EGFR-Mutant Cancers
- Some patients may be eligible for other clinical trials at Dana-Farber. You can learn more on the Center for Cancer Therapeutic Innovation (CCTI)’s website.
- There may also be trials available at other hospitals in the Boston area. Ask your doctor for help finding a trial that’s right for you.
Trial for Family Members of Patients with EGFR-Mutant Cancers and Their Communities
The EQUAL Study is evaluating a new blood test that aims to diagnose EGFR-positive lung cancer in East/Southeast Asian and Latinx individuals who are non-tobacco users. Although these populations are seeing an increase in lung cancer cases, often they are not eligible for routine lung cancer screening. The study is currently recruiting East/Southeast Asian or Latinx individuals in two groups:
- Group 1: 50-80 years old and have smoked less than 400 cigarettes in their lifetime
- Group 2: 40-49 years old, have smoked less than 400 cigarettes in their lifetime, and have an additional personal or family risk factor, like a familiar member with EGFR positive lung cancer or a previous cancer diagnosis (>5 years)
The study includes a blood draw, an optional survey, and an optional focus group. A gift card will be provided as compensation for each study component. To learn more and find out if you are eligible, please visit the study website or email equalstudy@dfci.harvard.edu.
Translational Research Studies
The Chen-Huang Center for EGFR Mutant Lung Cancers brings together clinical researchers and scientists dedicated to improving our understanding of the EGFR gene. As our researchers continue to gather data and results from studies like the ones below, they hope to uncover new details about the gene mutation that will lead to new standardized treatment options:
Collection of Specimens and Clinical Data from Subjects with Proven or Suspected Thoracic Malignancies
One of the key goals of the Chen-Huang Center is to build a "biobank" of patients with known EGFR gene mutations. To build this biobank, our thoracic disease center has a dedicated team of research data specialists who coordinate and facilitate consent enrollment of patients who have been seen in our clinics. Patients consent to allow the EGFR Center and our thoracic physicians to follow their course of care through their medical records, in addition to making use of leftover tissue samples and blood banking for research purposes. Through analyses of the data obtained from our patients' medical records and linking this information to their samples, the EGFR Center can conduct this research. The EGFR Center continues to assess our patients' treatment outcomes, determine which treatment works best against the EGFR driver, and confirm the ways acquired resistance may occur in patients who had EGFR-related targeted treatment. We hope this continued research will translate to the creation of newly approved standard of care treatments for this patient population.
Biology of Young Lung Cancer Study
Pasi A. Jänne, MD, PhD, has an ongoing Biology of Young Lung Cancer study within Dana-Farber's Lowe Center for Thoracic Oncology. This study was created with the goal of better understanding why a significant percentage of lung cancer patients developed their diagnosis at the age of 45 years and younger. From the current literature, younger patients with lung cancer have been linked to a higher likelihood of harboring a gene mutation that drives their cancer. It has been noted that approximately 40% of young lung cancer patients harbor the EGFR gene. Within this context, the study aims to provide clinical germline testing of participants through a blood test, in addition to blood banking that can be used for future research purposes. We offer this study for internal Dana-Farber patients, as well as remote patients who reside in the United States.